Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.

Official Title

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Adagrasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)

Details

This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety, tolerability and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with KRAS G12C mutant NSCLC who have been exposed to prior G12C inhibitor and experienced progressive disease.

Keywords

Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease, NSCLC, KRAS G12C, Adagrasib, Avutometinib (VS-6766), Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Neoplasm Metastasis, Neoplasms, avutometinib (VS-6766) and adagrasib, avutometinib(VS-6766)+adagrasib, avutometinib (VS-6766)+adagrasib RP2D

Eligibility

Locations

  • UCSF Thoracic Oncology
    San Francisco California 94158 United States
  • University of Colorado Hospital Anschutz Cancer Pavllion
    Aurora Colorado 80045 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Verastem, Inc.
ID
NCT05375994
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 85 study participants
Last Updated